Intervacc Ab

Biostapro Ab

Guss, Bengt

Flock, Jan-ingmar

Bergman, Rune

Flock, Margareta

Janzon, Kenneth

Jacobsson, Karin

Frykberg, Lars

Lars Frykberg

Bengt Guss

Jan-Ingmar Flock

Margareta Flock

Karl Olov Zachrisson

Karin Jacobsson

Martin K Lindberg

Martin Nilsson

Kenneth Janzon

Rune Bergman

The present disclosure relates to immunogenic polypeptides, immunogenic compositions and vaccine compositions and use thereof for immunization of mammals susceptible toinfection. The disclosure also relates to methods for preparing, formulating and administrating such compositions.

Vaccine againstinfection

The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both ofsubsp.and subsp.and use thereof for immunization of non-human mammals againstsubsp.and/or subsp.. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component.

Immunizing composition

An antigenic composition comprises several antigenic components derived from antigens ofsubsp.or subsp., wherein at least one component is a fusion protein or polypeptide compromising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals againstsubsp.and/or subsp.. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.

Vaccine against streptococcal infections based on recombinant proteins

An antigenic composition comprises several antigenic components derived from antigens ofsubsp.or subsp., wherein at least one component is a fusion protein or polypeptide comprising two or more such antigens or fragments thereof. The antigenic composition may be used for immunization of mammals againstsubsp.and/or subsp.. A vaccine composition comprising the antigenic composition as immunizing component is also disclosed.

The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both ofsubsp.and subsp.and use thereof for immunization of non-human mammals againstsubsp.and/or subsp.. The present invention also discloses a vaccine composition comprising the aforesaid antigenic composition as immunizing component. The antigens used are EAG, FNZ, SFS, SEC and ScLC.

[object Object]

A new fibrinogen binding protein or polypeptide originating from coagulase negativebiotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negativeand a vaccine composition, comprising the protein or DNA.

Antibodies to a fibrinogen binding protein of staphylococcus epidermidis

A recombinant DNA molecule coding for a protein expressed by a bacterium, comprising the nucleotide sequence SEQ ID NO:1 or a homologous sequence, or a partial or homologous sequence of SEQ ID NO:1 coding for a polypeptide fragment comprising at least 15 amino acid residues, is described. Further, a protein expressed by such a bacterium or a polypeptide fragment comprising at least 15 amino acid residues, comprising the amino acid sequence SEQ ID NO:2 binds IgG and apolipoprotein H. Examples of the polypeptide fragments comprise the SEQ ID NO:3 through 6. These proteins and polypeptide fragments may be coupled to an inert carrier or matrix. Vectors comprising such a DNA molecule or the corresponding RNA molecule, and antibodies specifically binding to a polypeptide having an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:6, are also disclosed. The DNA or RNA molecules, the vectors and the antibodies mentioned may all be used in different types of vaccines against Staphylococcal infections. Moreover, a method of isolating and/or purifying apolipoprotein H from a liquid medium, especially from serum, is described.

Growing community of inventors

Storvreta, Sweden

Lars Frykberg